Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
11994-0016-01 11994-0016 samarium Sm 153 lexidronam Quadramet 50.0 mCi/mL Ancillary Therapy Radiopharmaceutical Samarium Sm 153 Intravenous May 19, 1997 In Use
55135-0132-01 55135-0132 SACITUZUMAB GOVITECAN TRODELVY 180.0 mg/1 Immunotherapy Drug Antibody Conjugate Trop-2 Intravenous Apr 23, 2020 In Use
00078-0698-02 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 28, 2017 In Use
00078-0698-51 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 28, 2017 In Use
00078-0698-99 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 28, 2017 In Use
00078-0698-19 00078-0698 RYDAPT Rydapt 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FLT3 Oral Apr 28, 2017 In Use
50881-0020-60 50881-0020 Ruxolitinib Jakafi 20.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50881-0010-01 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov 16, 2011 In Use
50881-0011-08 50881-0011 Ruxolitinib JAKAFI XR 11.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
50881-0025-60 50881-0025 Ruxolitinib Jakafi 25.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50881-0015-60 50881-0015 Ruxolitinib Jakafi 15.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50881-0022-08 50881-0022 Ruxolitinib JAKAFI XR 22.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
50881-0044-08 50881-0044 Ruxolitinib JAKAFI XR 44.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
50881-0033-08 50881-0033 ruxolitinib JAKAFI XR 33.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
50881-0010-60 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov 16, 2011 In Use
50881-0055-08 50881-0055 Ruxolitinib JAKAFI XR 55.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
50881-0005-60 50881-0005 Ruxolitinib Jakafi 5.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
69660-0202-91 69660-0202 Rucaparib Rubraca 250.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral May 1, 2017 Jul 31, 2025 No Longer Used
69660-0203-91 69660-0203 Rucaparib Rubraca 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec 19, 2016 Jul 31, 2025 No Longer Used
69660-0201-91 69660-0201 Rucaparib Rubraca 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec 19, 2016 Dec 31, 2025 No Longer Used
73536-0511-01 73536-0511 ROPEGINTERFERON ALFA-2B BESREMi Pen 500.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Jun 25, 2026 In Use
73536-0500-01 73536-0500 ROPEGINTERFERON ALFA-2B BESREMi 500.0 ug/mL Immunotherapy Cytokine Interferon Subcutaneous Nov 12, 2021 In Use
00703-3125-08 00703-3125 Romidepsin Romidepsin Chemotherapy Enzyme Inhibitor HDAC Intravenous Aug 1, 2018 Oct 31, 2021 No Longer Used
46026-0983-01 46026-0983 Romidepsin Istodax Chemotherapy Enzyme Inhibitor HDAC Intravenous Nov 5, 2009 May 28, 2010 No Longer Used
59572-0983-01 59572-0983 Romidepsin Istodax Chemotherapy Enzyme Inhibitor HDAC Jan 4, 2010 In Use

Found 12611 results — Export these results